YUMAB provides humanization of non-human antibodies, e.g., from hybridomas, using a combination of rational design and in vitro evolution techniques.

YUMAB has developed efficient techniques to “super”-humanize antibodies by employing optimized germline sequences. Humanization projects can be combined with other YUMAB service modules like antibody engineering, (e.g., affinity maturation, optimization for stability and production) or production in mammalian cells.

All steps can be performed in different final antibody product formats including full-length IgG, Fab, Yumab (scFv-Fc), scFv, various bispecific antibody formats or fusion proteins.